Biopharma & Life Sciences
Lowest say-on-pay support in Biopharma & Life Sciences
Every Biopharma & Life Sciences company's most recent say-on-pay vote, ranked by support, lowest first. Each company is shown at its own most recent fiscal year, and every figure carries the filing it was cited from.
The paid brief on any company in this table
Every company in this table has a free cited page. Positioning against the company’s disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
See the paid briefNo account needed.
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
| # | Company | Say-on-pay support |
|---|---|---|
| 1 | Arrowhead Pharmaceuticals ARWR fiscal 2025 | = |
| 2 | Pliant Therapeutics PLRX fiscal 2025 | = |
| 3 | Emergent BioSolutions EBS fiscal 2025 | = |
| 4 | Roivant Sciences ROIV fiscal 2024 | = |
| 5 | Akebia Therapeutics AKBA fiscal 2025 | = |
| 6 | Moderna MRNA fiscal 2025 | = |
| 7 | Zentalis Pharmaceuticals ZNTL fiscal 2025 | = |
| 8 | Sarepta Therapeutics SRPT fiscal 2025 | = |
| 9 | CRISPR Therapeutics AG CRSP fiscal 2025 | = |
| 10 | Bio-Techne Corporation TECH fiscal 2025 | = |
| 11 | Esperion Therapeutics ESPR fiscal 2025 | = |
| 12 | Twist Bioscience TWST fiscal 2025 | = |
| 13 | Altimmune ALT fiscal 2025 | = |
| 14 | Vericel VCEL fiscal 2025 | = |
| 15 | Exelixis EXEL fiscal 2025 | = |
| 16 | IQVIA Holdings IQV fiscal 2025 | = |
| 17 | Arcellx ACLX fiscal 2024 | = |
| 18 | Rhythm Pharmaceuticals RYTM fiscal 2025 | = |
| 19 | Elanco Animal Health ELAN fiscal 2025 | = |
| 20 | Pacific BioSciences of California PACB fiscal 2025 | = |
| 21 | Incyte INCY fiscal 2025 | = |
| 22 | Standard Biotools LAB fiscal 2025 | = |
| 23 | Seres Therapeutics MCRB fiscal 2025 | = |
| 24 | NRC Health NRC fiscal 2025 | = |
| 25 | Zoetis ZTS fiscal 2025 | = |
| 26 | Heron Therapeutics HRTX fiscal 2025 | = |
| 27 | Recursion Pharmaceuticals RXRX fiscal 2025 | = |
| 28 | BioMarin Pharmaceutical BMRN fiscal 2025 | = |
| 29 | Coherus Oncology CHRS fiscal 2025 | = |
| 30 | Insmed Incorporated INSM fiscal 2025 | = |
| 31 | Quanterix QTRX fiscal 2025 | = |
| 32 | Waters WAT fiscal 2025 | = |
| 33 | Mettler Toledo International MTD fiscal 2025 | = |
| 34 | Pfizer PFE fiscal 2025 | = |
| 35 | IDEAYA Biosciences IDYA fiscal 2025 | = |
| 36 | UroGen Pharma URGN fiscal 2025 | = |
| 37 | KalVista Pharmaceuticals KALV fiscal 2025 | = |
| 38 | Aclaris Therapeutics ACRS fiscal 2025 | = |
| 39 | Halozyme Therapeutics HALO fiscal 2025 | = |
| 40 | Cogent Biosciences COGT fiscal 2025 | = |
| 41 | Abbott Laboratories ABT fiscal 2025 | = |
| 42 | Arcus Biosciences RCUS fiscal 2025 | = |
| 43 | Agilent Technologies A fiscal 2025 | = |
| 44 | Vanda Pharmaceuticals VNDA fiscal 2025 | = |
| 45 | Amphastar Pharmaceuticals AMPH fiscal 2025 | = |
| 46 | Gilead Sciences GILD fiscal 2025 | = |
| 47 | REGENXBIO Inc. RGNX fiscal 2025 | = |
| 48 | Medpace Holdings MEDP fiscal 2025 | = |
| 49 | AbCellera Biologics ABCL fiscal 2025 | = |
| 50 | Alnylam Pharmaceuticals ALNY fiscal 2025 | = |
| 51 | Neurocrine BioSciences NBIX fiscal 2025 | = |
| 52 | Allogene Therapeutics ALLO fiscal 2025 | = |
| 53 | Regeneron Pharmaceuticals REGN fiscal 2025 | = |
| 54 | Vertex Pharmaceuticals VRTX fiscal 2025 | = |
| 55 | Illumina ILMN fiscal 2025 | = |
| 56 | Ardelyx ARDX fiscal 2025 | = |
| 57 | Keros Therapeutics KROS fiscal 2025 | = |
| 58 | Biogen BIIB fiscal 2025 | = |
| 59 | Denali Therapeutics DNLI fiscal 2025 | = |
| 60 | Jazz Pharmaceuticals JAZZ fiscal 2025 | = |
| 61 | Charles River Laboratories International CRL fiscal 2025 | = |
| 62 | AbbVie ABBV fiscal 2025 | = |
| 63 | Merck & Co. MRK fiscal 2025 | = |
| 64 | Zymeworks ZYME fiscal 2024 | = |
| 65 | Syndax Pharmaceuticals SNDX fiscal 2024 | = |
| 66 | Atea Pharmaceuticals AVIR fiscal 2025 | = |
| 67 | Arvinas ARVN fiscal 2025 | = |
| 68 | Cryoport CYRX fiscal 2025 | = |
| 69 | Protagonist Therapeutics PTGX fiscal 2025 | = |
| 70 | Phathom Pharmaceuticals PHAT fiscal 2025 | = |
| 71 | Xeris Biopharma Holdings XERS fiscal 2025 | = |
| 72 | Johnson & Johnson JNJ fiscal 2025 | = |
| 73 | Apellis Pharmaceuticals APLS fiscal 2024 | = |
| 74 | Bristol Myers Squibb BMY fiscal 2025 | = |
| 75 | Biohaven BHVN fiscal 2025 | = |
| 76 | Ironwood Pharmaceuticals IRWD fiscal 2025 | = |
| 77 | BridgeBio Pharma BBIO fiscal 2025 | = |
| 78 | Bruker BRKR fiscal 2025 | = |
| 79 | Arcutis Biotherapeutics ARQT fiscal 2025 | = |
| 80 | Mirum Pharmaceuticals MIRM fiscal 2025 | = |
| 81 | Eli Lilly and Company LLY fiscal 2025 | = |
| 82 | Bio-Rad Laboratories BIO fiscal 2025 | = |
| 83 | Revvity RVTY fiscal 2025 | = |
| 84 | OPKO Health OPK fiscal 2025 | = |
| 85 | Ionis Pharmaceuticals IONS fiscal 2025 | = |
| 86 | Supernus Pharmaceuticals SUPN fiscal 2025 | = |
| 87 | Ultragenyx Pharmaceutical RARE fiscal 2025 | = |
| 88 | Xencor XNCR fiscal 2025 | = |
| 89 | Adaptive Biotechnologies ADPT fiscal 2025 | = |
| 90 | Amgen AMGN fiscal 2025 | = |
| 91 | Harvard Bioscience HBIO fiscal 2025 | = |
| 92 | Viatris VTRS fiscal 2025 | = |
| 93 | Avantor AVTR fiscal 2025 | = |
| 94 | Repligen RGEN fiscal 2025 | = |
| 95 | United Therapeutics Corporation UTHR fiscal 2025 | = |
| 96 | Cytokinetics CYTK fiscal 2025 | = |
| 97 | Travere Therapeutics TVTX fiscal 2025 | = |
| 98 | Rocket Pharmaceuticals RCKT fiscal 2025 | = |
| 99 | Amicus Therapeutics FOLD fiscal 2024 | = |
| 100 | Agios Pharmaceuticals AGIO fiscal 2025 | = |
| 101 | Kura Oncology KURA fiscal 2025 | = |
| 102 | Vaxcyte PCVX fiscal 2025 | = |
| 103 | Relay Therapeutics RLAY fiscal 2025 | = |
| 104 | PTC Therapeutics PTCT fiscal 2025 | = |
| 105 | Evolus EOLS fiscal 2025 | = |
| 106 | Schrodinger SDGR fiscal 2025 | = |
| 107 | Tango Therapeutics TNGX fiscal 2025 | = |
| 108 | 10x Genomics TXG fiscal 2025 | = |
| 109 | Maravai Lifesciences Holdings MRVI fiscal 2025 | = |
| 110 | Beam Therapeutics BEAM fiscal 2025 | = |
| 111 | Acadia Pharmaceuticals ACAD fiscal 2025 | = |
| 112 | Alkermes ALKS fiscal 2025 | = |
| 113 | Replimune Group REPL fiscal 2026 | = |
| 114 | Dyne Therapeutics DYN fiscal 2025 | = |
| 115 | Cytek Biosciences CTKB fiscal 2025 | = |
| 116 | Lyell Immunopharma LYEL fiscal 2025 | = |
116 of 130 Biopharma & Life Sciences companies shown. A company is omitted when this figure has not been disclosed in a form this page can cite.